A5017923691- Tuberculosis Research and Epidemiology
- Mycobacterium research and diagnosis
- Healthcare Systems and Reforms
- Pneumocystis jirovecii pneumonia detection and treatment
- Pharmaceutical Economics and Policy
- Pneumonia and Respiratory Infections
- Infectious Diseases and Tuberculosis
- HIV/AIDS Impact and Responses
- HIV, Drug Use, Sexual Risk
- Pharmaceutical Quality and Counterfeiting
- Healthcare Policy and Management
- Health Services Management and Policy
- Pharmaceutical studies and practices
- Computational Drug Discovery Methods
- Schizophrenia research and treatment
- Mental Health Treatment and Access
- Biosimilars and Bioanalytical Methods
- Global Public Health Policies and Epidemiology
- Diagnosis and treatment of tuberculosis
- Migration, Health and Trauma
- Mental Health and Psychiatry
- Global Maternal and Child Health
- Berberine and alkaloids research
- HIV, TB, and STIs Epidemiology
- Mental Health and Patient Involvement
Médecins Sans Frontières
2025
MSB Medical School Berlin
2022-2024
Médecins Sans Frontières
2024
Médecins Sans Frontières
2022-2023
Abstract Background Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Week all-oral bedaquiline, pretomanid, and linezolid (BPaL)–based regimens have demonstrated higher rates success been recommended by the World Health Organization. Operational research is urgently required to evaluate these non-trial settings. Methods This was a prospective cohort study with microbiologically confirmed...
The introduction of new and often shorter tuberculosis (TB) drug regimens affects the cost TB programmes.
We report the findings of a prospective laboratory diagnostic accuracy study to evaluate sensitivity, specificity, and predictive values Xpert MTB/RIF Ultra assay for Mycobacterium tuberculosis detection in fresh stool specimens from children under 15 years age with confirmed (TB) disease Dushanbe, Tajikistan. Six hundred eighty-eight (688) participants were enrolled April 2019 October 2021. identified 16 (2.3%) TB disease, defined as ≥1 sign/symptom plus microbiologic confirmation. With...
BACKGROUND: The WHO recommends the use of bedaquiline (BDQ) in longer, as well shorter, multidrug-resistant TB (MDR-TB) treatment regimens. However, resistance to this new drug is now emerging. We aimed describe characteristics patients Karakalpakstan, Uzbekistan, who were treated for MDR-TB and acquired BDQ during treatment.METHODS: performed a retrospective study routinely collected data Karakalpakstan between January 2015 December 2020. included on BDQ-containing regimens with baseline...
Tuberculosis (TB) programs depend on a continuous supply of large amounts high-quality TB drugs. When procure drugs from international suppliers, such as the Global Drug Facility, they can incur import costs for transport, customs clearance, and national transport. We assessed drug 18 longer (≥18 months), 10 shorter (9–12 8 short (≤6 months) regimens drug-sensitive (DS) multidrug-resistant (MDR)-TB treatment. Costs per regimen were estimated by multiplying recommended with 2021 Facility...
BACKGROUND: Tajikistan has a high burden of rifampicin-resistant TB (RR-TB), with 2,700 new cases estimated for 2021 (28/100,000 population). is spread among household members through close interaction and children exposed contact progress to disease rapidly frequently. METHODS: We retrospectively analysed programmatic data from tracing in Dushanbe over 50 months. calculated person-years follow-up, yield, number needed screen (NNS) test (NNT) find one case, time diagnosis. RESULTS: screened...
Tuberculosis (TB) drugs and their import are costly. We assessed how shorter TB drug regimens, which were non-inferior or superior in recent trials, can affect the costs for purchasing importing drugs.We estimated of 39 longer regimens using prices from Global Drug Facility cost estimates a program Karakalpakstan, Uzbekistan. trials compared with following present past World Health Organization recommendations.We an $4.19 $43 per standard 6-month drug-sensitive (DS)-TB regimen. A new 17-week...
BACKGROUND: Bedaquiline (BDQ) is widely used in the treatment of rifampicin-resistant TB (RR-TB). However, resistance to BDQ now emerging. There are no standardised regimens for BDQ-resistant TB. This study aims share experience managing primary METHODS: We performed a retrospective patients treated RR-TB Karakalpakstan, Uzbekistan, from January 2017 March 2022. identified with history exposure. describe baseline characteristics, and follow-up these patients. RESULTS: Twelve 1,930 (0.6%) had...
Since 2015 Médecins Sans Frontières (MSF) has been supporting the Ministry of Health (MoH) in Tonkolili district, Sierra Leone, with an integrated health care approach at community, primary centre (PHC), and hospital level. This programme is planned to be handed over MoH. To prepare for this handover, a qualitative study exploring elements successful handover was undertaken 2019. Focus group discussions (FGD) community members (n-48) in-depth interviews (IDI) MSF staff, leaders, MoH staff...
Tuberculosis (TB) often concentrates in groups of people with complex health and social issues, including alcohol use disorders (AUD). Risk TB, poor TB treatment outcomes, are substantially elevated who have AUD. Médecins sans Frontières the Belarus Ministry Health worked to improve adherence patients multi-drug or rifampicin resistant (MDR/RR)-TB harmful alcohol. In 2016, a person-centred, multidisciplinary, psychosocial support harm reduction programme delivered by doctors, counsellors,...
Abstract Background The Global Drug Facility (GDF) of the Stop TB Partnership was launched in 2001 with goal increasing access to quality-assured tuberculosis (TB) drugs and products. We aimed describe prices available from GDF over time assess trends. Methods searched internet, including an internet archive, for past recent Product Catalogs extracted listed prices. calculated lowest price most common drug formulations assuming similar active pharmaceutical ingredients (APIs) are substitutes...
The rate of TB in prison institutions is estimated to be 23 times higher than the general population. Limited documentation exists regarding screening Tajikistan's prisons. This study aims report findings from a conducted facilities Tajikistan.
<sec><title>BACKGROUND</title>Drug-resistant TB (DR-TB) remains a major public health threat. In 2022, Uzbekistan reported 2,117 cases of DR-TB, with 69% tested for fluoroquinolone resistance. Limited information is available on the prevalence resistance to bedaquiline, linezolid, and fluoroquinolone, which are key components all-oral treatment regimen rifampicin-resistant in Uzbekistan.</sec><sec><title>METHODS</title>A retrospective study was...
Abstract Background TB is concentrated in populations with complex health and social issues, including alcohol use disorders (AUD). We describe treatment adherence outcomes a person-centred, multidisciplinary, psychosocial support harm reduction intervention for people multidrug-resistant or rifampicin-resistant (MDR/RR-TB) harmful use. Methods An observational cohort study, multilevel mixed-effects logistic regression survival analysis living Minsk admitted MDR/RR-TB AUD during January...
Background . Import of medical supplies is common, but limited knowledge about import costs and their structure introduces uncertainty to budget planning, cost management, cost-effectiveness analysis health programs. We aimed estimate the a tuberculosis (TB) program in Uzbekistan, including specific imported items. Methods developed framework that applies costing accounting costs. First, transport costs, customs-related cargo weight, unit weights, quantities ordered were gathered for major...
No abstract available.
INTRODUCTION The total duration of treatment for rifampicin-resistant tuberculosis (RR-TB) in Belarus prior to December 2022 was 18-20 months. efficacy with such regimens is low, the WHO’s Global TB Report suggesting that around 73% 2018. development effective short RR-TB urgent. In Belarus, six-month long all-oral used patients RR-TB, under operational research conditions, following WHO recommendations. METHODS A preliminary assessment effectiveness containing bedaquiline, pretomanid,...
No abstract available.
No abstract available.